<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862537</url>
  </required_header>
  <id_info>
    <org_study_id>PD Ext</org_study_id>
    <nct_id>NCT00862537</nct_id>
  </id_info>
  <brief_title>Evaluation of Long-term Effect of Resonator Therapy on Parkinson's Disease (PD)</brief_title>
  <official_title>An Open-label Extension Study for Subjects Previously Treated Either in Pilot I or Pilot II Studies of the Application of Magnetic Fields Using the Resonator for the Treatment of Parkinson's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>pico-tesla Magnetic Therapies, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>pico-tesla Magnetic Therapies, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An extension study for subjects with prior participation in previous resonator studies using
      low level magnetic fields to treat some of the symptoms of idiopathic Parkinson's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Change in Parkinson's Disease Questionnaire-39 Single Index Score (PDQ-39SI)From Baseline to Study Endpoint of 11 Months</measure>
    <time_frame>baseline and 11 months</time_frame>
    <description>The Parkinson's Disease Questionnaire (PDQ-39) is a 39-item quality of life questionnaire for patients with Parkinson's Disease (PD) that evaluates the 8 dimensions of mobility, activities of daily living, emotional well-being, stigma, social support, cognition, and communication. The PDQ-39 Single Index (SI) score is the weighted addition of scores on all 8 dimension and ranges from 0 (no disease impact) to 100 (severe disease impact).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">18</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Active Resonator magnetic field therapy</arm_group_label>
    <description>Administration of active magnetic fields with the Resonator Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resonator Device</intervention_name>
    <description>active pico-tesla magnetic fields treatment for Parkinson's disease individuals</description>
    <arm_group_label>Active Resonator magnetic field therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Previous participants enrolled in one of two prior pico-tesla Magnetic Therapies Resonator
        device studies using magnetic fields for treating Parkinson's Disease (PD) symptoms.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior participation in pico-tesla pilot studies: NCT00779155 &amp; NCT00863226

          -  Willing and able to abstain from partaking in non-essential new treatments for
             Parkinson's disease symptoms during the course of participation of the study.

          -  Will and able to abstain from all non-essential new medications that could affect PD
             and/or any of its associated symptoms for the duration of the study.

          -  Willing to notify the investigator right away of any changes in medication use or
             therapies that is prescribed and deemed necessary by the subjects physicians.

          -  Adequate contraceptive measures for female subjects

          -  Capable of giving full written informed consent

        Exclusion Criteria:

          -  Not a participant in IRC#'s 07102 or 07021

          -  No active brain tumors, strokes, hydrocephalus

          -  Chronic pain not associated with PD

          -  Any other condition which might prevent subject from comfortably sitting for 1.5 hours

          -  Consumption of medications that can produce Parkinsonism type symptoms

          -  Major psychiatric disturbance

          -  Epilepsy

          -  HIv and other autoimmune disorders

          -  Cancer within last 2 years

          -  History of ECt

          -  Diabetic neuropathy

          -  Uncontrolled HTN

          -  Advanced Pulmonary disease

          -  Known heart conditions such as repetitive history of cardiac arrythmias

          -  Previous surgeries for PD

          -  Prosthetics comprised of ferrous materials

          -  Stents, only where there is also cardiac arrythmias, CHF, advanced valvular stenosis,
             unstable vital signs, extensive ischemic damage to heart muscle as a result of one or
             more heart attacks.

          -  Pacemakers

          -  Uncontrolled, unstable, or untreated medical illnesses which might potentially
             significantly affect the patient's health in the opinion of the investigator

          -  Consumption of more than 21 alcoholic drinks per week

          -  Pregnant, breast feeding or planning pregnancy

          -  Developmental disability or cognitive impairment

          -  Inability to maintain regular medication regime

          -  Inability to abstain from partaking in new non-essential PD tx., or medications

          -  Not willing to report physician mandated changes in medication and/or treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry I Jacobson, PhD., DMD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>pico-tesla Magnetic Therapies, LLC</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>March 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <results_first_submitted>May 13, 2011</results_first_submitted>
  <results_first_submitted_qc>June 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2011</results_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>pico-tesla Magnetic Therapies, LLC</name_title>
    <organization>pico-tesla Magnetic Therapies, LLC</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Resontaor Device Therapy</title>
          <description>active pico-tesla magnetic fields Resonator device therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Resontaor Device Therapy</title>
          <description>active pico-tesla magnetic fields Resonator device therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Parkinson's Disease Questionnaire-39 Single Index Score (PDQ-39SI)From Baseline to Study Endpoint of 11 Months</title>
        <description>The Parkinson’s Disease Questionnaire (PDQ-39) is a 39-item quality of life questionnaire for patients with Parkinson’s Disease (PD) that evaluates the 8 dimensions of mobility, activities of daily living, emotional well-being, stigma, social support, cognition, and communication. The PDQ-39 Single Index (SI) score is the weighted addition of scores on all 8 dimension and ranges from 0 (no disease impact) to 100 (severe disease impact).</description>
        <time_frame>baseline and 11 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Resontaor Device Therapy</title>
            <description>active pico-tesla magnetic fields Resonator device therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Parkinson's Disease Questionnaire-39 Single Index Score (PDQ-39SI)From Baseline to Study Endpoint of 11 Months</title>
          <description>The Parkinson’s Disease Questionnaire (PDQ-39) is a 39-item quality of life questionnaire for patients with Parkinson’s Disease (PD) that evaluates the 8 dimensions of mobility, activities of daily living, emotional well-being, stigma, social support, cognition, and communication. The PDQ-39 Single Index (SI) score is the weighted addition of scores on all 8 dimension and ranges from 0 (no disease impact) to 100 (severe disease impact).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Resontaor Device Therapy</title>
          <description>active pico-tesla magnetic fields Resonator device therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allen S. Braswell CEO</name_or_title>
      <organization>Pico-Tesla Magnetic Therapies, LLC</organization>
      <phone>303 795-3222</phone>
      <email>abraswell@pico-tesla.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

